ReviewInternational journal of oncology2025
Decoding the role of cancer stem cells in digestive tract tumors: Mechanisms and therapeutic implications (Review).
Review in International journal of oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Chemoresistance in the era of immunotherapy: challenges and novel combinatorial strategies for digestive system tumors.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer stem cells (CSCs) are a distinct subpopulation of cells within tumors, characterized by their ability to self‑renew, differentiate and promote tumorigenesis. CSCs have critical roles in the initiation, progression and therapeutic resistance of digestive tract tumors, including in esophageal, gastric, colorectal and pancreatic cancer. The present review comprehensively explores the biology of CSCs, their interactions with the tumor microenvironment and their clinical relevance in predicting patient prognosis and guiding treatment strategies. The emerging therapeutic approaches that target CSCs, including pathway inhibitors, monoclonal antibodies and combination therapies, are also discussed, highlighting the potential of these strategies to improve patient outcomes in digestive tract cancer types. Additionally, future research directions and challenges in developing effective CSC‑targeted therapies are addressed, emphasizing the need for innovative strategies to overcome treatment resistance and increase therapeutic efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.